(Q51631869)

8 April 2018

title

Treatment of the hyperlipidemia of the nephrotic syndrome: a controlled trial. (English)

1 reference

8 April 2018

1 reference

1 reference

Valeri A

1

1 reference

8 April 2018

Gelfand J

series ordinal

2

1 reference

8 April 2018

Blum C

series ordinal

3

1 reference

8 April 2018

Appel GB

series ordinal

4

1 reference

8 April 2018

publication date

1 December 1986

1 reference

8 April 2018

American Journal of Kidney Diseases

published in

1 reference

8 April 2018

volume

8

1 reference

8 April 2018

issue

6

1 reference

8 April 2018

page(s)

388-396

1 reference

8 April 2018

Serum lipid and lipoprotein alterations in nephrosis

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

The causal role of plasma albumin deficiency in experimental nephrotic hyperlipemia and hypercholesteremia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Relationship between concentrations of albumin and lipids in plasma of experimentally nephrotic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Ischaemic heart-disease complicating nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Ischaemic heart-disease as a complication of nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Does the nephrotic syndrome increase the risk of cardiovascular disease?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Cardiovascular Disease and the Nephrotic Syndrome: the other Side of the Coin

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

The Nephrotic Syndrome and Ischaemic Heart Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Status of the coronary arteries in the nephrotic syndrome. Analysis of 20 necropsy patients aged 15 to 35 years to determine if coronary atherosclerosis is accelerated

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

RISK FACTORS IN CORONARY HEART DISEASE. AN EVALUATION OF SEVERAL SERUM LIPIDS AS PREDICTORS OF CORONARY HEART DISEASE; THE FRAMINGHAM STUDY

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Probability of Middle-Aged Men Developing Coronary Heart Disease in Five Years

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

The Tromsø heart-study. High-density lipoprotein and coronary heart-disease: a prospective case-control study

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

High-density lipoproteins in myocardial infarction survivors

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

High density lipoproteins and atherosclerosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Hyperlipoproteinemia in nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Lipid and apolipoprotein levels in patients with nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Hyperlipidaemia in untreated nephrotic syndrome, increased production or decreased removal?

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Lipoproteins in experimental nephrosis: Plasma levels and composition

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

High density lipoproteinuria in nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Urinary high density lipoprotein in minimal change glomerular disease and chronic glomerulopathies

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Experimental nephrotic syndrome in the rat induced by puromycin aminonucleoside. Plasma and urinary lipoproteins

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Relationship among the concentrations of serum lipoproteins and changes in their chemical composition in patients with untreated nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

The mechanism of hyperlipidaemia in nephrotic syndrome--role of low albumin and the LCAT reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

The hyperlipidemia of the nephrotic syndrome. Relation to plasma albumin concentration, oncotic pressure, and viscosity

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Effect of diet on serum lipoproteins in a population with a high risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Diet, lipoproteins, and the progression of coronary atherosclerosis. The Leiden Intervention Trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Acute Muscular Syndrome Associated with Administration of Clofibrate

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Complications during clofibrate treatment of nephrotic-syndrome hyperlipoproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Studies on the synthesis and secretion of serum lipoproteins by rat liver slices

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Studies on the turnover of triglyceride and esterified cholesterol in subjects with the nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Plasma Triglyceride Metabolism in the Adult Nephrotic Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

Probucol with colestipol in the treatment of hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1016%2FS0272-6386%2886%2980164-0

7 January 2021

10.1016/S0272-6386(86)80164-0

Identifiers

DOI

1 reference

8 April 2018

1 reference

8 April 2018